AIM ImmunoTech Inc AIM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AIM is a good fit for your portfolio.
News
-
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
-
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
-
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
-
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
-
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
-
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
-
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
-
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Trading Information
- Previous Close Price
- $0.44
- Day Range
- $0.40–0.45
- 52-Week Range
- $0.32–0.75
- Bid/Ask
- $0.39 / $0.40
- Market Cap
- $20.36 Mil
- Volume/Avg
- 89,269 / 224,925
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 105.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
- Website
- https://www.aimimmuno.com
Valuation
|
Metric
|
AIM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.25 |
Price/Sales | 105.00 |
Price/Cash Flow | — |
Price/Earnings
AIM
Financial Strength
|
Metric
|
AIM
|
|---|---|
Quick Ratio | 1.65 |
Current Ratio | 1.68 |
Interest Coverage | — |
Quick Ratio
AIM
Profitability
|
Metric
|
AIM
|
|---|---|
Return on Assets (Normalized) | −91.06% |
Return on Equity (Normalized) | −108.76% |
Return on Invested Capital (Normalized) | −106.85% |
Return on Assets
AIM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rmjzbsrms | Ktf | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bxqmhgbm | Lkltng | $108.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qmcvzlln | Rrjlsk | $105.3 Bil | |
MRNA
| Moderna Inc | Lxvxfsb | Vhxv | $47.0 Bil | |
ARGX
| argenx SE ADR | Tqnlsfsr | Mwrm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lmdfvdk | Plnn | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jwvvnprr | Vtlmwc | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lqkrdcbsn | Wkgzpt | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gpqyhqtzs | Lvjrgm | $12.6 Bil | |
INCY
| Incyte Corp | Ydtqpbmqt | Jgbfh | $12.0 Bil |